STING-Activating Polymer-Drug Conjugates for Cancer Immunotherapy

Taylor L. Sheehy,Alexander J. Kwiatkowski,Karan Arora,Blaise R. Kimmel,Jacob A. Schulman,Katherine N. Gibson-Corley,John T. Wilson

DOI: https://doi.org/10.1101/2024.03.23.585817

2024-04-12

Abstract:The stimulator of interferon genes (STING) pathway links innate and adaptive antitumor immunity and therefore plays an important role in cancer immune surveillance. This has prompted widespread development of STING agonists for cancer immunotherapy, but pharmacological barriers continue to limit the clinical impact of STING agonists and motivate the development of drug delivery systems to improve their efficacy and/or safety. To address these challenges, we developed SAPCon, a STING-activating polymer-drug conjugate platform based on strain-promoted azide-alkyne cycloaddition of dimeric-amidobenzimidazole (diABZI) STING agonists to hydrophilic polymer chains through an enzyme-responsive chemical linker. To synthesize a first-generation SAPCon, we designed a diABZI prodrug modified with a DBCO reactive handle with a cathepsin B-cleavable spacer for intracellular drug release and conjugated this to pendant azide groups on a 100kDa poly(dimethyla acrylamide- -azide methacrylate) copolymer backbone to increase circulation time and enable passive tumor accumulation. We found that intravenously administered SAPCon accumulated at tumor sites, where it was endocytosed by tumor-associated myeloid cells, resulting in increased STING activation in tumor tissue. Consequently, SAPCon promoted an immunogenic tumor microenvironment, characterized by increased frequency of activated macrophages and dendritic cells and improved infiltration of CD8 T cells, resulting in inhibition of tumor growth, prolonged survival, and enhanced response to anti-PD-1 immune checkpoint blockade in orthotopic breast cancer models. Collectively, these studies position SAPCon as a modular and programmable platform for improving the efficacy of systemically administered STING agonists for cancer immunotherapy.

Bioengineering

What problem does this paper attempt to address?

The main focus of this paper is to explore how to improve the efficacy and safety of STING agonists in cancer immunotherapy by designing a new drug platform called SAPCon (STING-Activating Polymer-Drug Conjugates). The STING (stimulator of interferon genes) pathway plays a critical role in tumor immune surveillance, but current STING agonists face challenges in pharmacokinetics and biodistribution in clinical applications.

The researchers developed a polymer-drug conjugate based on a strain-promoted azide-alkyne cycloaddition reaction, in which a dinitrophenyl benzimidazole (diABZI) STING agonist was linked to a water-soluble polymer chain via an enzyme-responsive linker. This conjugate is designed to increase blood circulation time, promote tumor accumulation, and enhance STING activation in tumor tissue through intracellular enzyme-mediated drug release.

Experimental results showed that intravenous injection of SAPCon could accumulate at tumor sites, be taken up by tumor-associated myeloid cells, thereby enhancing STING activation, improving the tumor microenvironment, characterized by increased activated macrophages and dendritic cells, increased infiltration of CD8+ T cells, inhibiting tumor growth, prolonging survival, and enhancing response to PD-1 immune checkpoint blockade.

The paper also discussed the limitations of systemic administration of STING agonists, such as rapid clearance, insufficient tumor accumulation, and limited intracellular delivery. SAPCon provides a strategy for enhancing systemic administration of STING agonists in cancer immunotherapy through its modularity and programmability.

In summary, this paper aims to address how to improve the pharmacokinetic properties of STING agonists through innovative drug carrier technologies, targeting tumors more effectively, enhancing immune responses, and thus improving the effectiveness of cancer immunotherapy.